IFNG and cancer: Alternative replacement of anti-HER2 CD4+ Th1 would be to administer Th1 cytokines such as systemic IFN-γ or IFN-γ-inducing agents like STING and Toll like receptor agonists, may be combined with anti-HER2 targeted therapies as an immunotherapeutic approach to treat HER2 positive cancer patients [92, 93].